10-hydroxy-11,12-epoxyeicosa-5,8,14-trienoic acid profile

10-hydroxy-11,12-epoxyeicosa-5,8,14-trienoic acid, also known as **10-HETE**, is a bioactive lipid belonging to the **hydroxyeicosatetraenoic acids (HETEs)**.

**Structure and Synthesis:**

* It's a derivative of the omega-6 fatty acid **arachidonic acid (AA)**.
* 10-HETE is synthesized via the **cytochrome P450 monooxygenase pathway**, specifically by the enzyme **CYP4F2** (cytochrome P450, family 4, subfamily F, polypeptide 2).

**Biological Functions and Importance:**

10-HETE has a range of biological effects, including:

* **Vasodilation:** It can relax blood vessels, potentially playing a role in regulating blood pressure.
* **Inflammatory response:** 10-HETE can both promote and inhibit inflammation depending on the context. It can activate neutrophils and contribute to tissue damage, but also can inhibit the production of certain pro-inflammatory mediators.
* **Cell growth and differentiation:** 10-HETE can influence the growth and differentiation of various cell types, including cancer cells.
* **Renal function:** It has been implicated in regulating renal blood flow and electrolyte balance.
* **Neuroplasticity:** Studies suggest that 10-HETE may play a role in brain development and neuronal function.

**Research Importance:**

10-HETE is a focus of research due to its diverse biological activities and potential involvement in various physiological and pathological processes. Some key areas of research include:

* **Cardiovascular disease:** Exploring its role in vascular health, blood pressure regulation, and atherosclerosis.
* **Inflammation:** Understanding its complex involvement in both promoting and resolving inflammation.
* **Cancer:** Investigating its potential as a target for cancer therapy or as a marker for tumor progression.
* **Renal disease:** Uncovering its influence on renal function and its potential as a biomarker for kidney disorders.
* **Neurological disorders:** Examining its role in brain development, neurotransmission, and potential contribution to neurological diseases.

**Overall, 10-HETE is a fascinating molecule with broad biological significance. Research into its diverse functions continues to expand our understanding of its role in health and disease.**

10-hydroxy-11,12-epoxyeicosa-5,8,14-trienoic acid: structure in 2nd source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5353667
MeSH ID	M0079673

Synonym
(5e,8e)-10-hydroxy-10-[3-[(e)-oct-2-enyl]oxiran-2-yl]deca-5,8-dienoic acid
10-hydroxy-11,12-epoxyeicosa-5,8,14-trienoic acid
5,8-decadienoic acid, 10-hydroxy-10-(3-(2-octenyl)oxiranyl)-

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (16.67)	18.7374
1990's	18 (60.00)	18.2507
2000's	3 (10.00)	29.6817
2010's	3 (10.00)	24.3611
2020's	1 (3.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	5 (16.13%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	26 (83.87%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
14,15-epoxy-5,8,11-eicosatrienoic acid 14,15-epoxy-5,8,11-eicosatrienoic acid: RN given refers to cpd without isomeric designation	2.05	1	long-chain fatty acid
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	1.98	1	benzenes; phenyl acetates
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	1.97	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
allicin [no description available]	1.97	1	botanical anti-fungal agent; sulfoxide	antibacterial agent
1-hexadecyl-2-acetyl-glycero-3-phosphocholine Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	2.69	3	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
indo-1 pentaacetoxymethyl ester Indo-1 pentaacetoxymethyl ester: calcium-specific chelating agent; calcium ion fluorescent probe	1.99	1
bradykinin [no description available]	2.69	3	oligopeptide	human blood serum metabolite; vasodilator agent
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	3.08	5	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
nadp [no description available]	2.05	1
9-diazomethylanthracene 9-diazomethylanthracene: RN & N1 from 9th CI Form Index	1.98	1
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	1.96	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
8,11,14-eicosatrienoic acid 8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.	7.13	30	fatty acid 20:3; long-chain fatty acid	fungal metabolite; human metabolite; nutraceutical
arachidonic acid omega-9 hydroperoxide 12-HPETE: RN given refers to cpd without isomeric designation; 12-HPETE may be used inconsistently in literature as synonym for cpds with various tetraene-locants; caused dose-dependent constriction of cat coronary arteries. 12(S)-HPETE : The (S)-enantiomer of 12-HPETE.	4.69	5	HPETE	mouse metabolite
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	1.97	1	thromboxanes B	human metabolite; mouse metabolite
12-hydroxy-5,8,10-heptadecatrienoic acid 12-hydroxy-5,8,10-heptadecatrienoic acid: metabolite of arachidonic acid in blood platelet suspension; RN given refers to cpd without isomeric designation	1.98	1	hydroxy polyunsaturated fatty acid; long-chain fatty acid; trienoic fatty acid	metabolite
12-hydroxy-5,8,10,14-eicosatetraenoic acid 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)	2.9	4
8-hydroxy-11,12-epoxyeicosa-5,9,14-trienoic acid hepoxilin : Mono-hydroxy epoxy icosatrienoic acids which are generated along the 12-lipoxygenase pathway.	6.38	17
8,11,12-trihydroxy-5,9,14-eicosatrienoic acid 8,11,12-trihydroxy-5,9,14-eicosatrienoic acid: structure	2.67	3
11-glutathionylhepoxilin a3 11-glutathionylhepoxilin A3: structure in first source; RN refers to 8(R)-isomer	4.01	4
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	2.01	1	1,2-diacyl-sn-glycero-3-phosphocholine

Condition	Relationship Strength	Studies
Congenital Zika Syndrome [description not available]	2.21	1
Innate Inflammatory Response [description not available]	2.45	2
Microcephaly A congenital abnormality in which the CEREBRUM is underdeveloped, the fontanels close prematurely, and, as a result, the head is small. (Desk Reference for Neuroscience, 2nd ed.)	2.21	1
Viral Diseases [description not available]	2.21	1
Complications, Infectious Pregnancy [description not available]	2.21	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.21	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.45	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.21	1
Virus Diseases A general term for diseases caused by viruses.	2.21	1
Cystic Fibrosis of Pancreas [description not available]	2.11	1
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	2.11	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.03	1
Experimental Leukemia [description not available]	2.03	1
Alveolitis, Fibrosing [description not available]	2.03	1
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	2.03	1
Palmoplantaris Pustulosis [description not available]	2.41	2
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	2.41	2
Diabetes Mellitus, Adult-Onset [description not available]	2	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2	1

10-hydroxy-11,12-epoxyeicosa-5,8,14-trienoic acid

Description

Cross-References

Synonyms (3)

Research

Studies (30)

Market Indicators

Research Demand Index: 11.33

Study Types